Cargando…

Neutralisation de Sars-CoV-2 Delta après vaccination hétérologue

Detalles Bibliográficos
Autor principal:	Manus, Jean-Marie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Masson SAS. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570092/ https://www.ncbi.nlm.nih.gov/pubmed/34754334 http://dx.doi.org/10.1016/S1773-035X(21)00232-X

Ejemplares similares

Myopéricardite persistante après une vaccination hétérologue à ARNm anti-SRAS-CoV-2
por: Wu, Kai Yi, et al.
Publicado: (2023)

Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history
por: Lavezzo, Enrico, et al.
Publicado: (2022)

Highly Thermotolerant SARS-CoV-2 Vaccine Elicits Neutralising Antibodies against Delta and Omicron in Mice
por: Jansen van Vuren, Petrus, et al.
Publicado: (2022)

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination
por: Davis, Chris, et al.
Publicado: (2021)

Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia
por: Parry, Helen, et al.
Publicado: (2022)

AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC
por: Wall, Emma C, et al.
Publicado: (2021)

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination
por: Behrens, Georg MN, et al.
Publicado: (2021)

Neutralisation of SARS‐CoV‐2 by anatomical embalming solutions
por: Quondamatteo, Fabio, et al.
Publicado: (2021)

Un vaccin… et après ?
por: Manus, Jean-Marie
Publicado: (2021)

Brève : Vaccins Sars-CoV-2 : contre-indications
por: Manus, Jean-Marie
Publicado: (2021)

Orbitopathie inflammatoire après vaccin ARN messager anti-SARS-CoV-2
por: Grunenwald, S., et al.
Publicado: (2023)

Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
por: Kemp, SA, et al.
Publicado: (2020)

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage
por: Arora, Prerna, et al.
Publicado: (2023)

Évaluation de l'immunogénicité après vaccination COVID-19 hétérologue ChAdOx1-nCoV19/BNT162b2 et homologue BNT162b2/BNT162b2– Cohorte ANRS0001S COV-POPART
por: Lachâtre, M., et al.
Publicado: (2022)

Sars-CoV-2, de nouvelles données
por: Manus, Jean-Marie
Publicado: (2020)

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study
por: Souza, William M, et al.
Publicado: (2021)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Un vaccin Sars-CoV-2 à deux cibles
por: Manus, Jean-Marie
Publicado: (2021)

Nuvaxovid, un nouveau vaccin anti-Sars-CoV-2
por: Manus, Jean-Marie
Publicado: (2022)

Sars-CoV-2, déjà une nouvelle génération de vaccins à ARN ?
por: Manus, Jean-Marie
Publicado: (2023)

At Least Three Doses of Leading Vaccines Essential for Neutralisation of SARS-CoV-2 Omicron Variant
por: Singanallur, Nagendrakumar B., et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants
por: Zhao, Xin, et al.
Publicado: (2021)

SARS-CoV-2 neutralising antibodies in Dogs and Cats in the United Kingdom
por: Smith, Shirley L., et al.
Publicado: (2021)

Des chiens dépisteurs de Sars-CoV-2
por: Manus, Jean-Marie
Publicado: (2022)

Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load
por: Migueres, Marion, et al.
Publicado: (2022)

Contre Sars-CoV-2 : un vaccin mais aussi le don de plasma
por: Manus, Jean-Marie
Publicado: (2021)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage
por: Gruell, Henning, et al.
Publicado: (2022)

Réactions cutanées retardées après vaccination contre le SARS-CoV-2 : étude CoVacskin
por: Darrigade, A.S., et al.
Publicado: (2022)

Brève : Sars-CoV-2 : le variant de Noël
por: Manus, Jean-Marie
Publicado: (2021)

Vaccin Sars-CoV-2 : et la France dans tout cela ?
por: Manus, Jean-Marie
Publicado: (2021)

Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma
por: Tonn, Torsten, et al.
Publicado: (2020)

Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice
por: Pang, Natalie Yan-Lin, et al.
Publicado: (2021)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants
por: Pallett, Scott J C, et al.
Publicado: (2022)

Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
por: Yamasoba, Daichi, et al.
Publicado: (2022)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Serum sample neutralisation of BBIBP-CorV and ZF2001 vaccines to SARS-CoV-2 501Y.V2
por: Huang, Baoying, et al.
Publicado: (2021)

A protein subunit vaccine booster following two doses of inactivated SARS-CoV-2 vaccine provides high neutralisation of SARS-CoV-2 and its variants in mice
por: Zhang, Rong, et al.
Publicado: (2022)

Sars-CoV-2 : variants préoccupants, un souci de plus ?
por: Manus, Jean-Marie
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9oktbd0mvr4h45oh4o166m2g0u